Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 25 entries
Sorted by: Best Match Show Resources per page
Increased lipogenesis in spite of upregulated hepatic 5'AMP-activated protein kinase in human non-alcoholic fatty liver.

Hepatology research : the official journal of the Japan Society of Hepatology

von Loeffelholz C, Döcke S, Lock JF, Lieske S, Horn P, Kriebel J, Wahl S, Singmann P, de Las Heras Gala T, Grallert H, Raschzok N, Sauer IM, Heller R, Jahreis G, Claus RA, Bauer M, Stockmann M, Birkenfeld AL, Pfeiffer AFH.
PMID: 27689765
Hepatol Res. 2017 Aug;47(9):890-901. doi: 10.1111/hepr.12825. Epub 2016 Nov 18.

AIMS: Molecular adaptations in human non-alcoholic fatty liver disease (NAFLD) are incompletely understood. This study investigated the main gene categories related to hepatic de novo lipogenesis and lipid oxidation capacity.METHODS: Liver specimens of 48 subjects were histologically classified according...

Cite
von Loeffelholz C, Döcke S, Lock JF, et al. Increased lipogenesis in spite of upregulated hepatic 5'AMP-activated protein kinase in human non-alcoholic fatty liver. Hepatol Res. 2016;47(9):890-901doi: 10.1111/hepr.12825.
von Loeffelholz, C., Döcke, S., Lock, J. F., Lieske, S., Horn, P., Kriebel, J., Wahl, S., Singmann, P., de Las Heras Gala, T., Grallert, H., Raschzok, N., Sauer, I. M., Heller, R., Jahreis, G., Claus, R. A., Bauer, M., Stockmann, M., Birkenfeld, A. L., & Pfeiffer, A. F. H. (2017). Increased lipogenesis in spite of upregulated hepatic 5'AMP-activated protein kinase in human non-alcoholic fatty liver. Hepatology research : the official journal of the Japan Society of Hepatology, 47(9), 890-901. https://doi.org/10.1111/hepr.12825
von Loeffelholz, Christian, et al. "Increased lipogenesis in spite of upregulated hepatic 5'AMP-activated protein kinase in human non-alcoholic fatty liver." Hepatology research : the official journal of the Japan Society of Hepatology vol. 47,9 (2017): 890-901. doi: https://doi.org/10.1111/hepr.12825
von Loeffelholz C, Döcke S, Lock JF, Lieske S, Horn P, Kriebel J, Wahl S, Singmann P, de Las Heras Gala T, Grallert H, Raschzok N, Sauer IM, Heller R, Jahreis G, Claus RA, Bauer M, Stockmann M, Birkenfeld AL, Pfeiffer AFH. Increased lipogenesis in spite of upregulated hepatic 5'AMP-activated protein kinase in human non-alcoholic fatty liver. Hepatol Res. 2017 Aug;47(9):890-901. doi: 10.1111/hepr.12825. Epub 2016 Nov 18. PMID: 27689765.
Copy Download .nbib Format: NLM
Characterization of the Interaction Between the Small Regulatory Peptide SgrT and the EIICBGlc of the Glucose-Phosphotransferase System of E. coli K-12.

Metabolites

Kosfeld A, Jahreis K.
PMID: 24957761
Metabolites. 2012 Oct 16;2(4):756-74. doi: 10.3390/metabo2040756.

Escherichia coli is a widely used microorganism in biotechnological processes. An obvious goal for current scientific and technical research in this field is the search for new tools to optimize productivity. Usually glucose is the preferred carbon source in...

Cite
Kosfeld A, Jahreis K. Characterization of the Interaction Between the Small Regulatory Peptide SgrT and the EIICBGlc of the Glucose-Phosphotransferase System of E. coli K-12. Metabolites. 2012;2(4):756-74doi: 10.3390/metabo2040756.
Kosfeld, A., & Jahreis, K. (2012). Characterization of the Interaction Between the Small Regulatory Peptide SgrT and the EIICBGlc of the Glucose-Phosphotransferase System of E. coli K-12. Metabolites, 2(4), 756-74. https://doi.org/10.3390/metabo2040756
Kosfeld, Anne, and Jahreis, Knut. "Characterization of the Interaction Between the Small Regulatory Peptide SgrT and the EIICBGlc of the Glucose-Phosphotransferase System of E. coli K-12." Metabolites vol. 2,4 (2012): 756-74. doi: https://doi.org/10.3390/metabo2040756
Kosfeld A, Jahreis K. Characterization of the Interaction Between the Small Regulatory Peptide SgrT and the EIICBGlc of the Glucose-Phosphotransferase System of E. coli K-12. Metabolites. 2012 Oct 16;2(4):756-74. doi: 10.3390/metabo2040756. PMID: 24957761; PMCID: PMC3901232.
Copy Download .nbib Format: NLM
Analysis and Design of Stimulus Response Curves of E. coli.

Metabolites

Kremling A, Goehler A, Jahreis K, Nees M, Auerbach B, Schmidt-Heck W, Kökpinar O, Geffers R, Rinas U, Bettenbrock K.
PMID: 24957765
Metabolites. 2012 Nov 12;2(4):844-71. doi: 10.3390/metabo2040844.

Metabolism and signalling are tightly coupled in bacteria. Combining several theoretical approaches, a core model is presented that describes transcriptional and allosteric control of glycolysis in Escherichia coli. Experimental data based on microarrays, signalling components and extracellular metabolites are...

Cite
Kremling A, Goehler A, Jahreis K, et al. Analysis and Design of Stimulus Response Curves of E. coli. Metabolites. 2012;2(4):844-71doi: 10.3390/metabo2040844.
Kremling, A., Goehler, A., Jahreis, K., Nees, M., Auerbach, B., Schmidt-Heck, W., Kökpinar, O., Geffers, R., Rinas, U., & Bettenbrock, K. (2012). Analysis and Design of Stimulus Response Curves of E. coli. Metabolites, 2(4), 844-71. https://doi.org/10.3390/metabo2040844
Kremling, Andreas, et al. "Analysis and Design of Stimulus Response Curves of E. coli." Metabolites vol. 2,4 (2012): 844-71. doi: https://doi.org/10.3390/metabo2040844
Kremling A, Goehler A, Jahreis K, Nees M, Auerbach B, Schmidt-Heck W, Kökpinar O, Geffers R, Rinas U, Bettenbrock K. Analysis and Design of Stimulus Response Curves of E. coli. Metabolites. 2012 Nov 12;2(4):844-71. doi: 10.3390/metabo2040844. PMID: 24957765; PMCID: PMC3901224.
Copy Download .nbib Format: NLM
Patterns of Biodynamic Milk Fatty Acid Composition Explained by A Climate-Geographical Approach.

Animals : an open access journal from MDPI

Baars T, Wohlers J, Rohrer C, Lorkowski S, Jahreis G.
PMID: 30909506
Animals (Basel). 2019 Mar 22;9(3). doi: 10.3390/ani9030111.

BACKGROUND: Biodynamic dairy production is based on a land-related animal production without the additional input of N-fertilizers. The concentrate level per cow is low. This affects the yield level of animals and product quality outcomes.METHODS: We examined the milk...

Cite
Baars T, Wohlers J, Rohrer C, et al. Patterns of Biodynamic Milk Fatty Acid Composition Explained by A Climate-Geographical Approach. Animals (Basel). 2019;9(3)doi: 10.3390/ani9030111.
Baars, T., Wohlers, J., Rohrer, C., Lorkowski, S., & Jahreis, G. (2019). Patterns of Biodynamic Milk Fatty Acid Composition Explained by A Climate-Geographical Approach. Animals : an open access journal from MDPI, 9(3), . https://doi.org/10.3390/ani9030111
Baars, Ton, et al. "Patterns of Biodynamic Milk Fatty Acid Composition Explained by A Climate-Geographical Approach." Animals : an open access journal from MDPI vol. 9,3 (2019). doi: https://doi.org/10.3390/ani9030111
Baars T, Wohlers J, Rohrer C, Lorkowski S, Jahreis G. Patterns of Biodynamic Milk Fatty Acid Composition Explained by A Climate-Geographical Approach. Animals (Basel). 2019 Mar 22;9(3). doi: 10.3390/ani9030111. PMID: 30909506; PMCID: PMC6466038.
Copy Download .nbib Format: NLM
Long-Term Safety of Rituximab in Rheumatoid Arthritis: Analysis From the SUNSTONE Registry.

Arthritis care & research

Winthrop KL, Saag K, Cascino MD, Pei J, John A, Jahreis A, Haselkorn T, Furst DE.
PMID: 30295434
Arthritis Care Res (Hoboken). 2018 Oct 08; doi: 10.1002/acr.23781. Epub 2018 Oct 08.

OBJECTIVE: To evaluate the long-term safety of rituximab in an observational cohort of patients with rheumatoid arthritis (RA) who had an inadequate response to ≥ 1 antitumor necrosis factor therapies in the United States (SUNSTONE Registry).METHODS: In this prospective,...

Cite
Winthrop KL, Saag K, Cascino MD, et al. Long-Term Safety of Rituximab in Rheumatoid Arthritis: Analysis From the SUNSTONE Registry. Arthritis Care Res (Hoboken). 2018;doi: 10.1002/acr.23781.
Winthrop, K. L., Saag, K., Cascino, M. D., Pei, J., John, A., Jahreis, A., Haselkorn, T., & Furst, D. E. (2018). Long-Term Safety of Rituximab in Rheumatoid Arthritis: Analysis From the SUNSTONE Registry. Arthritis care & research, . https://doi.org/10.1002/acr.23781
Winthrop, Kevin L, et al. "Long-Term Safety of Rituximab in Rheumatoid Arthritis: Analysis From the SUNSTONE Registry." Arthritis care & research vol. (2018). doi: https://doi.org/10.1002/acr.23781
Winthrop KL, Saag K, Cascino MD, Pei J, John A, Jahreis A, Haselkorn T, Furst DE. Long-Term Safety of Rituximab in Rheumatoid Arthritis: Analysis From the SUNSTONE Registry. Arthritis Care Res (Hoboken). 2018 Oct 08; doi: 10.1002/acr.23781. Epub 2018 Oct 08. PMID: 30295434; PMCID: PMC6806017.
Copy Download .nbib Format: NLM
Choice of anesthesia and data analysis method strongly increases sensitivity of 18F-FDG PET imaging during experimental epileptogenesis.

PloS one

Jahreis I, Bascuñana P, Ross TL, Bankstahl JP, Bankstahl M.
PMID: 34818362
PLoS One. 2021 Nov 24;16(11):e0260482. doi: 10.1371/journal.pone.0260482. eCollection 2021.

PURPOSE: Alterations in brain glucose metabolism detected by 2-deoxy-2-[18F]-fluoro-D-glucose (18F-FDG) positron emission tomography (PET) may serve as an early predictive biomarker and treatment target for epileptogenesis. Here, we aimed to investigate changes in cerebral glucose metabolism before induction of...

Cite
Jahreis I, Bascuñana P, Ross TL, et al. Choice of anesthesia and data analysis method strongly increases sensitivity of 18F-FDG PET imaging during experimental epileptogenesis. PLoS One. 2021;16(11):e0260482doi: 10.1371/journal.pone.0260482.
Jahreis, I., Bascuñana, P., Ross, T. L., Bankstahl, J. P., & Bankstahl, M. (2021). Choice of anesthesia and data analysis method strongly increases sensitivity of 18F-FDG PET imaging during experimental epileptogenesis. PloS one, 16(11), e0260482. https://doi.org/10.1371/journal.pone.0260482
Jahreis, Ina, et al. "Choice of anesthesia and data analysis method strongly increases sensitivity of 18F-FDG PET imaging during experimental epileptogenesis." PloS one vol. 16,11 (2021): e0260482. doi: https://doi.org/10.1371/journal.pone.0260482
Jahreis I, Bascuñana P, Ross TL, Bankstahl JP, Bankstahl M. Choice of anesthesia and data analysis method strongly increases sensitivity of 18F-FDG PET imaging during experimental epileptogenesis. PLoS One. 2021 Nov 24;16(11):e0260482. doi: 10.1371/journal.pone.0260482. eCollection 2021. PMID: 34818362; PMCID: PMC8612569.
Copy Download .nbib Format: NLM
Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial.

Annals of the rheumatic diseases

Westhovens R, Rigby WFC, van der Heijde D, Ching DWT, Stohl W, Kay J, Chopra A, Bartok B, Matzkies F, Yin Z, Guo Y, Tasset C, Sundy JS, Jahreis A, Mozaffarian N, Messina OD, Landewé RB, Atsumi T, Burmester GR.
PMID: 33452004
Ann Rheum Dis. 2021 Jan 15; doi: 10.1136/annrheumdis-2020-219213. Epub 2021 Jan 15.

OBJECTIVES: To investigate efficacy and safety of the Janus kinase-1 inhibitor filgotinib in patients with active rheumatoid arthritis (RA) with limited or no prior methotrexate (MTX) exposure.METHODS: This 52-week, phase 3, multicentre, double-blind clinical trial (NCT02886728) evaluated once-daily oral...

Cite
Westhovens R, Rigby WFC, van der Heijde D, et al. Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial. Ann Rheum Dis. 2021;doi: 10.1136/annrheumdis-2020-219213.
Westhovens, R., Rigby, W. F. C., van der Heijde, D., Ching, D. W. T., Stohl, W., Kay, J., Chopra, A., Bartok, B., Matzkies, F., Yin, Z., Guo, Y., Tasset, C., Sundy, J. S., Jahreis, A., Mozaffarian, N., Messina, O. D., Landewé, R. B., Atsumi, T., & Burmester, G. R. (2021). Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial. Annals of the rheumatic diseases, . https://doi.org/10.1136/annrheumdis-2020-219213
Westhovens, René, et al. "Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial." Annals of the rheumatic diseases vol. (2021). doi: https://doi.org/10.1136/annrheumdis-2020-219213
Westhovens R, Rigby WFC, van der Heijde D, Ching DWT, Stohl W, Kay J, Chopra A, Bartok B, Matzkies F, Yin Z, Guo Y, Tasset C, Sundy JS, Jahreis A, Mozaffarian N, Messina OD, Landewé RB, Atsumi T, Burmester GR. Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial. Ann Rheum Dis. 2021 Jan 15; doi: 10.1136/annrheumdis-2020-219213. Epub 2021 Jan 15. PMID: 33452004; PMCID: PMC8142453.
Copy Download .nbib Format: NLM
Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years.

Annals of the rheumatic diseases

Winthrop KL, Tanaka Y, Takeuchi T, Kivitz A, Matzkies F, Genovese MC, Jiang D, Chen K, Bartok B, Jahreis A, Besuyen R, Burmester GR, Gottenberg JE.
PMID: 34740884
Ann Rheum Dis. 2021 Nov 05; doi: 10.1136/annrheumdis-2021-221051. Epub 2021 Nov 05.

OBJECTIVE: To characterise safety of the Janus kinase-1 preferential inhibitor filgotinib in patients with moderately to severely active rheumatoid arthritis.METHODS: Data were integrated from seven trials (NCT01668641, NCT01894516, NCT02889796, NCT02873936, NCT02886728, NCT02065700, NCT03025308). Results are from placebo (PBO)-controlled (through...

Cite
Winthrop KL, Tanaka Y, Takeuchi T, et al. Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years. Ann Rheum Dis. 2021;doi: 10.1136/annrheumdis-2021-221051.
Winthrop, K. L., Tanaka, Y., Takeuchi, T., Kivitz, A., Matzkies, F., Genovese, M. C., Jiang, D., Chen, K., Bartok, B., Jahreis, A., Besuyen, R., Burmester, G. R., & Gottenberg, J. E. (2021). Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years. Annals of the rheumatic diseases, . https://doi.org/10.1136/annrheumdis-2021-221051
Winthrop, Kevin L, et al. "Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years." Annals of the rheumatic diseases vol. (2021). doi: https://doi.org/10.1136/annrheumdis-2021-221051
Winthrop KL, Tanaka Y, Takeuchi T, Kivitz A, Matzkies F, Genovese MC, Jiang D, Chen K, Bartok B, Jahreis A, Besuyen R, Burmester GR, Gottenberg JE. Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years. Ann Rheum Dis. 2021 Nov 05; doi: 10.1136/annrheumdis-2021-221051. Epub 2021 Nov 05. PMID: 34740884.
Copy Download .nbib Format: NLM
Trans fatty acid isomers and the trans-9/trans-11 index in fat containing foods.

European journal of lipid science and technology : EJLST

Kuhnt K, Baehr M, Rohrer C, Jahreis G.
PMID: 22164125
Eur J Lipid Sci Technol. 2011 Oct;113(10):1281-1292. doi: 10.1002/ejlt.201100037.

To determine trans fatty acid (TFA) distribution of contemporary foods, especially regarding individual trans octadecenoic acids (trans C18:1), 339 German foods of six categories (semi-solid fats, deep-fried potato products, bakery products, confectioneries, instant products and butter) were analysed using...

Cite
Kuhnt K, Baehr M, Rohrer C, et al. Trans fatty acid isomers and the trans-9/trans-11 index in fat containing foods. Eur J Lipid Sci Technol. 2011;113(10):1281-1292doi: 10.1002/ejlt.201100037.
Kuhnt, K., Baehr, M., Rohrer, C., & Jahreis, G. (2011). Trans fatty acid isomers and the trans-9/trans-11 index in fat containing foods. European journal of lipid science and technology : EJLST, 113(10), 1281-1292. https://doi.org/10.1002/ejlt.201100037
Kuhnt, Katrin, et al. "Trans fatty acid isomers and the trans-9/trans-11 index in fat containing foods." European journal of lipid science and technology : EJLST vol. 113,10 (2011): 1281-1292. doi: https://doi.org/10.1002/ejlt.201100037
Kuhnt K, Baehr M, Rohrer C, Jahreis G. Trans fatty acid isomers and the trans-9/trans-11 index in fat containing foods. Eur J Lipid Sci Technol. 2011 Oct;113(10):1281-1292. doi: 10.1002/ejlt.201100037. PMID: 22164125; PMCID: PMC3229980.
Copy Download .nbib Format: NLM
Foetal cord blood contains higher portions of n-3 and n-6 long-chain PUFA but lower portions of trans C18:1 isomers than maternal blood.

Food & nutrition research

Schlörmann W, Kramer R, Lochner A, Rohrer C, Schleussner E, Jahreis G, Kuhnt K.
PMID: 26617388
Food Nutr Res. 2015 Nov 27;59:29348. doi: 10.3402/fnr.v59.29348. eCollection 2015.

BACKGROUND/OBJECTIVE: An adequate supply of long-chain polyunsaturated fatty acids (LC PUFA) promotes foetal health and development, whereas generally, trans fatty acids (tFA) are considered to negatively interfere with LC PUFA metabolism. Nevertheless, to date, limited data concerning separate trans...

Cite
Schlörmann W, Kramer R, Lochner A, et al. Foetal cord blood contains higher portions of n-3 and n-6 long-chain PUFA but lower portions of trans C18:1 isomers than maternal blood. Food Nutr Res. 2015;59:29348doi: 10.3402/fnr.v59.29348.
Schlörmann, W., Kramer, R., Lochner, A., Rohrer, C., Schleussner, E., Jahreis, G., & Kuhnt, K. (2015). Foetal cord blood contains higher portions of n-3 and n-6 long-chain PUFA but lower portions of trans C18:1 isomers than maternal blood. Food & nutrition research, 5929348. https://doi.org/10.3402/fnr.v59.29348
Schlörmann, Wiebke, et al. "Foetal cord blood contains higher portions of n-3 and n-6 long-chain PUFA but lower portions of trans C18:1 isomers than maternal blood." Food & nutrition research vol. 59 (2015): 29348. doi: https://doi.org/10.3402/fnr.v59.29348
Schlörmann W, Kramer R, Lochner A, Rohrer C, Schleussner E, Jahreis G, Kuhnt K. Foetal cord blood contains higher portions of n-3 and n-6 long-chain PUFA but lower portions of trans C18:1 isomers than maternal blood. Food Nutr Res. 2015 Nov 27;59:29348. doi: 10.3402/fnr.v59.29348. eCollection 2015. PMID: 26617388; PMCID: PMC4663192.
Copy Download .nbib Format: NLM
Osteopontin Links Myeloid Activation and Disease Progression in Systemic Sclerosis.

Cell reports. Medicine

Gao X, Jia G, Guttman A, DePianto DJ, Morshead KB, Sun KH, Ramamoorthi N, Vander Heiden JA, Modrusan Z, Wolters PJ, Jahreis A, Arron JR, Khanna D, Ramalingam TR.
PMID: 33294861
Cell Rep Med. 2020 Nov 17;1(8):100140. doi: 10.1016/j.xcrm.2020.100140. eCollection 2020 Nov 17.

Progressive lung fibrosis is a major cause of mortality in systemic sclerosis (SSc) patients, but the underlying mechanisms remain unclear. We demonstrate that immune complexes (ICs) activate human monocytes to promote lung fibroblast migration partly via osteopontin (OPN) secretion,...

Cite
Gao X, Jia G, Guttman A, et al. Osteopontin Links Myeloid Activation and Disease Progression in Systemic Sclerosis. Cell Rep Med. 2020;1(8):100140doi: 10.1016/j.xcrm.2020.100140.
Gao, X., Jia, G., Guttman, A., DePianto, D. J., Morshead, K. B., Sun, K. H., Ramamoorthi, N., Vander Heiden, J. A., Modrusan, Z., Wolters, P. J., Jahreis, A., Arron, J. R., Khanna, D., & Ramalingam, T. R. (2020). Osteopontin Links Myeloid Activation and Disease Progression in Systemic Sclerosis. Cell reports. Medicine, 1(8), 100140. https://doi.org/10.1016/j.xcrm.2020.100140
Gao, Xia, et al. "Osteopontin Links Myeloid Activation and Disease Progression in Systemic Sclerosis." Cell reports. Medicine vol. 1,8 (2020): 100140. doi: https://doi.org/10.1016/j.xcrm.2020.100140
Gao X, Jia G, Guttman A, DePianto DJ, Morshead KB, Sun KH, Ramamoorthi N, Vander Heiden JA, Modrusan Z, Wolters PJ, Jahreis A, Arron JR, Khanna D, Ramalingam TR. Osteopontin Links Myeloid Activation and Disease Progression in Systemic Sclerosis. Cell Rep Med. 2020 Nov 17;1(8):100140. doi: 10.1016/j.xcrm.2020.100140. eCollection 2020 Nov 17. PMID: 33294861; PMCID: PMC7691442.
Copy Download .nbib Format: NLM
Sonographic Evaluation of Gastric Residual Volume during Enteral Nutrition in Critically Ill Patients Using a Miniaturized Ultrasound Device.

Journal of clinical medicine

Jahreis T, Kretschmann J, Weidner N, Volk T, Meiser A, Groesdonk HV.
PMID: 34768380
J Clin Med. 2021 Oct 22;10(21). doi: 10.3390/jcm10214859.

BACKGROUND: To assess the risk of aspiration, nutrient tolerance, and gastric emptying of patients in ICUs, gastric ultrasound can provide information about the gastric contents. Using established formulas, the gastric residual volume (GRV) can be calculated in a standardized...

Cite
Jahreis T, Kretschmann J, Weidner N, et al. Sonographic Evaluation of Gastric Residual Volume during Enteral Nutrition in Critically Ill Patients Using a Miniaturized Ultrasound Device. J Clin Med. 2021;10(21)doi: 10.3390/jcm10214859.
Jahreis, T., Kretschmann, J., Weidner, N., Volk, T., Meiser, A., & Groesdonk, H. V. (2021). Sonographic Evaluation of Gastric Residual Volume during Enteral Nutrition in Critically Ill Patients Using a Miniaturized Ultrasound Device. Journal of clinical medicine, 10(21), . https://doi.org/10.3390/jcm10214859
Jahreis, Tizian, et al. "Sonographic Evaluation of Gastric Residual Volume during Enteral Nutrition in Critically Ill Patients Using a Miniaturized Ultrasound Device." Journal of clinical medicine vol. 10,21 (2021). doi: https://doi.org/10.3390/jcm10214859
Jahreis T, Kretschmann J, Weidner N, Volk T, Meiser A, Groesdonk HV. Sonographic Evaluation of Gastric Residual Volume during Enteral Nutrition in Critically Ill Patients Using a Miniaturized Ultrasound Device. J Clin Med. 2021 Oct 22;10(21). doi: 10.3390/jcm10214859. PMID: 34768380; PMCID: PMC8585036.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 25 entries